Experts express alarm that GLP-1 RAs may trigger or worsen eating disorders. But is there any role they might play in binge ...

Both GLP-1 RAs and SGLT2is are associated with a reduced risk for Alzheimer disease and related dementias among people with T2D.

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.

in which GLP-1 RAs have recently shown promise. We believe the potential of this proprietary combination could lead to value-creating opportunities and may open up a new avenue of research within ...

As earlier outlined, short-term studies in animals and humans have shown GLP-1 to have some direct vasorelaxation ... receiving any of these LA GLP1-RAs. However, there are several ongoing trials ...

Increased awareness and knowledge of GLP-1/GIP receptor agonists among women, with insights into public perspectives on ...

During oral arguments, the defendants contended that the plaintiffs could not support their allegations that Novo Nordisk and ...

In a study of adults with diabetes and gastrointestinal (GI) motility abnormalities, over 75% had GI motility abnormalities.

Semaglutide promising alternative treatment for chronic myopathy of hyperkalemic periodic paralysis suggests a case report ...